THEOCLEAR-200
Clinical safety rating: caution
Comprehensive clinical and safety monograph for THEOCLEAR-200 (THEOCLEAR-200).
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to bronchodilation. It also acts as an adenosine receptor antagonist and may enhance diaphragmatic contractility.
| Metabolism | Hepatic via CYP1A2, CYP2E1, and CYP3A4. Follows Michaelis-Menten kinetics with dose-dependent metabolism. |
| Excretion | Renal: ~10% unchanged; Hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination; metabolites (caffeine, 3-methylxanthine, 1-methyluric acid) excreted renally. Fecal excretion negligible. |
| Half-life | Terminal elimination half-life: ~8 hours (range 3–12 hours) in adults; prolonged in hepatic impairment, heart failure, COPD, and neonates. Significantly shorter in smokers (4–6 hours). |
| Protein binding | ~40% bound, primarily to albumin. |
| Volume of Distribution | 0.3–0.7 L/kg; approx. 0.45 L/kg in adults. Increased Vd in premature infants, cirrhosis, and CHF. Distributes freely into breast milk and across placenta. |
| Bioavailability | Oral: 96% (nearly complete). Rectal: variable (70–90%). Intravenous: 100%. |
| Onset of Action | Oral immediate-release: 30–60 minutes. Intravenous: within minutes. Rectal: similar to oral. Peak effect correlates with serum concentration. |
| Duration of Action | Oral immediate-release: 6–8 hours. Extended-release formulations: 12–24 hours. Bronchodilation persists as long as serum levels remain in therapeutic range (10–20 mcg/mL). |
Theophylline 200 mg orally every 6 hours (extended-release) or as directed by serum theophylline concentrations. Usual adult target: 400-600 mg/day.
| Dosage form | TABLET |
| Renal impairment | No specific GFR-based dose adjustments are recommended; however, monitor serum theophylline concentrations in patients with renal impairment as clearance may be reduced. |
| Liver impairment | Child-Pugh Class A: reduce dose by 50%. Child-Pugh Class B: reduce dose by 75%. Child-Pugh Class C: avoid use or use with extreme caution; monitor serum levels frequently. Dose adjustments should be guided by serum theophylline concentrations. |
| Pediatric use | Initial dose: 5 mg/kg orally every 6 hours (immediate-release) or 10-15 mg/kg/day divided every 12 hours (extended-release). Titrate based on serum theophylline levels (target 5-15 mcg/mL). Maximum dose: 16 mg/kg/day up to 400 mg/day for children 1-9 years; 16 mg/kg/day up to 600 mg/day for children 9-16 years. |
| Geriatric use | Start at lowest effective dose (e.g., 200 mg once daily) and titrate slowly. Monitor serum theophylline concentrations closely due to reduced clearance in elderly. Target serum level: 5-10 mcg/mL. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for THEOCLEAR-200 (THEOCLEAR-200).
| Breastfeeding | Excreted in breast milk; milk-to-plasma ratio approximately 0.6-0.7. Considered compatible with breastfeeding but monitor infant for irritability, insomnia, and tachycardia. Accumulation may occur in neonates with reduced clearance. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Crosses placenta; limited data suggest no major malformations but fetal tachycardia and jitteriness reported. Second and third trimesters: Risk of neonatal apnea, hypoglycemia, and hypocalcemia due to beta-adrenergic stimulation. Avoid during labor due to risk of maternal tachycardia and fetal distress. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to theophylline or any component of the formulation.
| Precautions | ["Narrow therapeutic index; serum levels must be monitored to avoid toxicity.","Use with caution in patients with peptic ulcer, seizure disorders, or cardiac arrhythmias.","Coadministration with drugs that affect CYP1A2 (e.g., cimetidine, fluoroquinolones, macrolides) can alter theophylline clearance.","May cause tachycardia, palpitations, and central nervous system stimulation."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and serum theophylline levels (therapeutic range 10-20 mcg/mL). Fetal monitoring including heart rate and growth ultrasound. Assess for maternal signs of toxicity (tachycardia, arrhythmias, seizures). |
| Fertility Effects | Limited data; no established adverse effects on fertility in humans. Animal studies show no impairment at clinically relevant doses. |